Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
A short pre-surgical non-therapeutic trial involving postmenopausal women with newly
diagnosed eR+, HeR2-negative operable breast cancers. After undergoing a core needle biopsy
for tissue acquisition, study participants will take a 7- to 56-day (1-8 weeks) course of
letrozole in accordance with standard of care. They will then undergo definitive surgical
resection of their primary tumor (mastectomy vs lumpectomy) as per standard of care
guidelines.